Senior Management

Sang Hwan Seo, Ph.D.

Sang Hwan Seo, Ph.D. is a Senior Research Scientist and Lab Manager at IVI. He has been leading projects focused on the development of virus vaccines and establishing T cell assays for clinical studies of vaccines.

Dr. Seo joined IVI in 2018 as a Research Scientist and Lab Manager. He led a project for the establishment of the first WHO international standard for MERS-CoV antibody. Following the COVID-19 pandemic, Dr. Seo conducted a project to establish the first WHO international standard and reference panel for anti-SARS-CoV-2 antibody. He also developed and validated the Focus Reduction Neutralization Test (FRNT), an assay used to assess SARS-CoV-2-specific neutralizing antibodies. The validated FRNT was utilized at IVI to support various pre-clinical and clinical studies for vaccine development and transferred to the Korea National Institute of Health (KNIH). He also has been developing vaccine against human adenovirus type 55 and hepatitis A virus in collaboration with KNIH, Armed Forces Medical Research Institute and Gyeongbuk Institute for Bio-industry.

Prior to joining IVI, Dr. Seo held positions at the Korea Disease Control and Prevention Agency (KDCA)/KNIH, Korea Research Institute of Bioscience & Biotechnology, and Interpark Bio-convergence center. His research at these institutions involved the development of sensitive detection methods for bio-threat and respiratory infectious pathogens, adjuvant study using outer membrane vesicle as well as studying the immune regulation by microRNA.

Dr. Seo received a B.S. from the Collage of Pharmacy at Yeungnam University and received a Ph.D. from Pohang University of Science and Technology (POSTECH).